Robert F. Kennedy Jr., serving as health secretary, delivered a keynote address at a conference hosted by Children’s Health Defense, an organization he helped found. STAT frames the speech as a return to Kennedy’s earlier anti-vaccine activism and positions it within his broader MAHA movement agenda. The timing of the conference — shortly before midterm elections — was described as politically significant for the administration’s health agenda and for Kennedy’s efforts to make vaccine skepticism central to his legacy.
Over more than 20 minutes at the CHD gathering, Kennedy repeatedly cast doubt on the safety profile of vaccines. He displayed a hepatitis B vaccine package insert and questioned the clinical trial evidence, asserting that trials were small, lacked placebos, and monitored participants only briefly. He argued that the public has “no idea” about the risk profile of shots that have been administered tens of millions of times.
Kennedy acknowledged that serious harm from vaccines is likely “very rare,” but nevertheless suggested — without presenting scientific evidence in the speech — that vaccines could be associated with the rise in chronic illnesses in the United States. He cited the list of adverse events in vaccine inserts and highlighted a total count of reported events, naming conditions such as diabetes, sudden infant death syndrome, autoimmune diseases, asthma, and allergies as among those listed in manufacturers’ materials.
The article notes that manufacturers are required to disclose conditions reported after vaccination, but that such listings do not establish causal relationships or reliable frequency estimates. STAT emphasizes that reporting of an event after vaccination does not in itself demonstrate causation.
Kennedy singled out the early clinical data for the hepatitis B vaccine, questioning the relevance of an initial trial involving 147 participants and suggesting it would not meet typical approval standards. STAT reports that at the time the Food and Drug Administration accepted that trial alongside data from thousands of babies who had received an older version of the hepatitis B vaccine. The article further states that larger trials and post-market surveillance conducted after the vaccine’s introduction have provided additional evidence supporting its efficacy and safety.
STAT also reports that universal newborn hepatitis B vaccination was associated with a 99% drop in chronic hepatitis B infections among children and teenagers. The article notes that the Trump administration later ended the policy of universal newborn vaccination.
According to Kennedy’s remarks, the Department of Health and Human Services is undertaking several vaccine-related projects. He said HHS is researching more than 150 of the most serious adverse events reported after vaccination to determine whether any could be linked to particular vaccines. He also described interagency work including a task force review of the safety, timing, and sequence of childhood vaccinations and a large-scale project aggregating health data from Medicare, Medicaid, states, and private insurers.
These initiatives were presented by Kennedy as evidence that his administration is prioritizing investigation into reported vaccine harms, though the article does not provide details about study designs, timelines, or interim findings.
Kennedy criticized the current adverse-event reporting infrastructure and said HHS plans to make the Vaccine Adverse Event Reporting System (VAERS) more user friendly. He stated that the department will compensate physicians for the time they spend submitting information about possible vaccine side effects and injuries, but did not elaborate on the mechanism or the amount of compensation.
The article references Kennedy’s previous public comments about automating VAERS to increase data collection. STAT does not provide further operational details or timelines for implementation of these proposed VAERS changes.
Kennedy mentioned measles only briefly during the speech, saying that even rare vaccine-related harms deserve attention and that a single child death from measles receives headlines. STAT notes that measles has been rapidly spreading in the U.S. and cites at least four deaths in Pennsylvania linked to recent outbreaks. The piece also describes widespread concern among physicians, biotech companies, and other public health stakeholders about the administration’s vaccine policy shifts.
The article further situates Kennedy’s remarks within a political context: despite pushback from parts of the medical and public health communities, Kennedy said he had the support of the White House and that the president was a “strong and steadfast friend.”
Kennedy concluded his remarks to applause. STAT reports that after he left the stage, the next speaker announced for the event was Andrew Wakefield, identified in the article as the discredited British physician whose late-1990s work helped spark the modern anti-vaccine movement.
All factual points in this article are taken from the STAT News report. Where STAT attributes claims to Kennedy — including suggestions of causal links between vaccines and chronic disease, descriptions of clinical-trial shortcomings, and plans for VAERS reform — those claims are reported as his statements. STAT provides counterpoints and context in several places, noting established evidence for hepatitis B vaccine effectiveness, the distinction between reported adverse events and causation, and the absence of supporting evidence for some of Kennedy’s broader assertions. The STAT piece does not provide technical details, timelines, or data for the HHS research projects Kennedy described, and those specifics were not reported in the source.